Developer docs
API playgroundTry for free, no card

Search company profiles

DxTerity

Full company profile

uuid0004lqx

Namestring
DxTerity
Legal namestring
DxTerity Diagnostics Inc.
Websiteurl
dxterity.com
Company typeenum
Private
Founded yearint
2006
Descriptiontext

DxTerity Diagnostics Inc. is a Torrance, California-based molecular diagnostics company founded in 2006 that develops RNA-based precision diagnostic tests for autoimmune diseases. Its core technology is the proprietary DxDirect platform, which uses non-enzymatic Chemical Ligation Probe Assay (CLPA) chemistry to convert mRNA targets into uniquely-sized ligation products detected by PCR amplification and capillary electrophoresis on a ThermoFisher 3500Dx instrument — a workflow that bypasses sample purification and supports up to 1,500 samples per day per system with a 6-hour sample-to-answer turnaround. Its companion DxCollect product line (MicroCollection Device and Blood Collection Tube) provides 14-day ambient-temperature RNA stabilization, enabling at-home fingerstick self-collection and standard mail shipping without cold-chain logistics.

The company's commercial test portfolio includes the Type 1 Interferon (IFN-1) focused assay, which stratifies systemic lupus erythematosus (SLE) patients for likely response to anifrolumab, and the Modular Immune Profile (MIP) targeted panel covering gene signatures for IFN-1, B-cells, T-cells, neutrophils, and plasmablasts for use in lupus, rheumatoid arthritis, and Sjögren's syndrome. The platform is operated from a CAP-accredited, CLIA-certified, ISO 13485:2016-compliant laboratory and is approved for distribution across all 50 US states plus the European Union (via CE Mark for DxCollect). Note that these tests are LDTs and have not been cleared or approved by the FDA, and require a physician order.

DxTerity generates revenue through three streams: per-test laboratory diagnostic services ordered by physicians (including via at-home DxCollect kits), sale of DxCollect collection devices, and custom development services — Clinical Trial Assays (CTAs) and Companion Diagnostics (CDx) — for biopharmaceutical partners engaged in autoimmune drug development. Customer segments include rheumatology practices and academic medical centers ordering tests, biopharmaceutical companies (including multiple top-10 global firms) using DxCollect for clinical trial patient stratification, and nonprofit research organizations such as the Lupus Research Alliance and Lupus Therapeutics. Distribution combines a physician-ordered domestic model, at-home self-collection, and direct B2B enterprise partnerships with pharma.

Short descriptiontext

DxTerity is a California-based molecular diagnostics company that runs a CAP-accredited, CLIA-certified laboratory offering RNA-based genomic tests and at-home blood collection devices for autoimmune disease management, serving physicians, autoimmune patients, and biopharmaceutical partners developing companion diagnostics.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersTorrance, United States
HQ citystring
Torrance
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
RNA-based diagnostics, autoimmune disease testing, companion diagnostics development, clinical trial assays, blood collection devices
Industry5 codes
PRIMARYHLAHAHAJ
Diabetes Digital Therapeutics & Dose Decision Support (Bolus Calculators)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Diabetes Care Devices (CGM, Insulin Delivery)
SECONDARYHLAAALAN
Laboratory Developed Tests (LDTs) & Specialized Clinical Lab Assays
SECONDARYHLAAALAF
Companion Diagnostics (CDx) & Therapy Selection Assays
SECONDARYHLAAAMAL
Biomarker Assay & Reagent Development (LDT/IVD assay design, antibodies/standards/controls)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAAALAK
Autoimmune & Allergy Diagnostics
NAICS code2 codes
  • Medical Laboratories621511
  • In-Vitro Diagnostic Substance Manufacturing325413
SIC code2 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Services-Medical Laboratories8071
Product category
Molecular Diagnostics
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Laboratory Testing Services
TypeOne Time License
Description

RNA-based diagnostic testing services performed in DxTerity's CAP-accredited, CLIA-certified laboratory. Tests ordered by physicians for patients with autoimmune diseases. Revenue generated per test with 7 business day turnaround time available.

dxterity.com
2DxCollect Products
TypeHardware Sales
Description

Sale of blood collection products including DxCollect MicroCollection Device (MCD) and Blood Collection Tube (BCT). Products enable fingerstick self-collection with 14-day RNA stabilization at room temperature for shipping.

dxterity.com
3Development Services
TypeProfessional Services
Description

Custom diagnostic development services for pharmaceutical companies including Clinical Trial Assays (CTA) and Companion Diagnostics (CDx). Services span from concept through commercialization including assay design, regulatory guidance, and manufacturing support.

dxterity.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Supply Chain, Infrastructure
Pricing details1 tier
1Laboratory testing services - physician-ordered tests
ModelOtherBilling cadencePay-as-you-go
Notes

Quote-based pricing. Tests ordered through physician. Contact DxTerity at 310-537-7857 or info@dxterity.com for pricing information.

dxterity.com
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 2 records shown
1DxDirect
Description

CLPA-based testing platform for direct-from-blood and tissue RNA testing using non-enzymatic chemical ligation technology.

dxterity.com
+1 more record
Core offering1 text field

DxTerity operates a CAP-accredited, CLIA-certified clinical laboratory that develops and delivers RNA-powered precision diagnostics for autoimmune diseases. The portfolio includes physician-ordered tests (Type 1 Interferon and Modular Immune Profile), proprietary at-home blood collection devices (DxCollect MCD and BCT) with 14-day ambient RNA stabilization, a CLPA-based testing platform (DxDirect), and custom Clinical Trial Assay and Companion Diagnostic development services for pharmaceutical partners.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Over 1 million tests processed
+3 more records
Product overview1 text field

DxTerity offers a unified portfolio of RNA-based diagnostic products organized around two core platforms: DxCollect (blood collection devices) and DxDirect (testing platform). The DxCollect product line includes the MicroCollection Device (MCD) for fingerstick self-collection and the Blood Collection Tube (BCT) for venipuncture, both providing 14-day ambient RNA stabilization. The DxDirect platform enables high-throughput RNA testing without sample purification. Testing products include the Type 1 Interferon (IFN-1) focused assay and the Modular Immune Profile (MIP) targeted panel assay. The company also provides Development Services for pharmaceutical partners including assay design, clinical studies, regulatory guidance, and manufacturing for companion diagnostics.

Product and service6 records
1Type 1 Interferon (IFN-1) Test
CategoryDiagnostic Test
Description

Focused assay measuring interferon pathway activity to identify SLE patients more likely to experience moderate to severe disease, helping identify candidates for targeted therapies such as anifrolumab. Requires a physician order.

2Modular Immune Profile (MIP) Test
CategoryDiagnostic Test
Description

Targeted panel assay providing broad immune system analysis including gene signatures for IFN-1, B-cells, T-cells, plasmablasts, neutrophils, and other immune pathways to characterize autoimmune disease and therapeutic response.

3DxCollect MCD (MicroCollection Device)
CategoryBlood Collection Product
Description

Finger stick self-collection device enabling blood draw with 14-day RNA stabilization at room temperature, allowing ambient shipping for DNA and RNA genomic testing without dry ice.

4DxCollect BCT (Blood Collection Tube)
CategoryBlood Collection Product
Description

Evacuated blood draw tube (1 mL draw) with 14-day ambient RNA stabilization, compatible with standard venipuncture workflows.

5DxDirect Kits
CategoryTesting Platform
Description

RNA-based testing kits utilizing a unique analytical process that eliminates sample purification and enables high-throughput processing (up to 1500 samples per day per system, 6 hour sample-to-answer).

6Development Services
CategoryService Offering
Description

Custom diagnostic development services for pharmaceutical companies including assay design, analytical validation, clinical studies, regulatory guidance, manufacturing, and data management for Clinical Trial Assays (CTA) and Companion Diagnostics (CDx).

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2023-05-23
Description

Strategic partnership for the 5-year Lupus Landmark Study - a prospective longitudinal study targeting enrollment of up to 3,500 adults diagnosed with systemic lupus erythematosus (SLE). DxTerity provides testing using its Modular Immune Profile (MIP) assay including gene signatures for IFN-1, B-cells, T-cells, and other immune pathways. The study aims to provide real-world data and clinical samples to evaluate therapy effectiveness and power precision medicine development for SLE.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2023-05-23
Description

Clinical research affiliate of Lupus Research Alliance collaborating on the Lupus Landmark Study. Partnership enables patient-centric, collaborative research resource (Lupus Nexus) for accelerating personalized treatments in lupus through large-scale genomic monitoring.

3Pharmaceutical Companies (Multiple)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-02-27
Description

DxCollect device deployed for patient stratification and monitoring in large-scale, direct-to-patient clinical studies. Multiple pharmaceutical companies use DxCollect for RNA preservation in clinical trials. Trusted by top ten global bio-pharmaceutical companies according to company statements.

dxterity.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

DxTerity has partnered with biotech and pharmaceutical industry participants in autoimmune to identify emerging biomarkers in therapeutic targeting. Targeted panel tests seek to establish claims across diagnostic, prognostic, and theranostic testing aims. Active in clinical trials with ongoing regulatory filings to establish standardized testing in clinical practice.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability1 record

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance11 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

DxTerity

Molecular Diagnosticsdxterity.com

DxTerity is a California-based molecular diagnostics company that runs a CAP-accredited, CLIA-certified laboratory offering RNA-based genomic tests and at-home blood collection devices for autoimmune disease management, serving physicians, autoimmune patients, and biopharmaceutical partners developing companion diagnostics.

What DxTerity does

DxTerity Diagnostics Inc. is a Torrance, California-based molecular diagnostics company founded in 2006 that develops RNA-based precision diagnostic tests for autoimmune diseases. Its core technology is the proprietary DxDirect platform, which uses non-enzymatic Chemical Ligation Probe Assay (CLPA) chemistry to convert mRNA targets into uniquely-sized ligation products detected by PCR amplification and capillary electrophoresis on a ThermoFisher 3500Dx instrument — a workflow that bypasses sample purification and supports up to 1,500 samples per day per system with a 6-hour sample-to-answer turnaround. Its companion DxCollect product line (MicroCollection Device and Blood Collection Tube) provides 14-day ambient-temperature RNA stabilization, enabling at-home fingerstick self-collection and standard mail shipping without cold-chain logistics.

The company's commercial test portfolio includes the Type 1 Interferon (IFN-1) focused assay, which stratifies systemic lupus erythematosus (SLE) patients for likely response to anifrolumab, and the Modular Immune Profile (MIP) targeted panel covering gene signatures for IFN-1, B-cells, T-cells, neutrophils, and plasmablasts for use in lupus, rheumatoid arthritis, and Sjögren's syndrome. The platform is operated from a CAP-accredited, CLIA-certified, ISO 13485:2016-compliant laboratory and is approved for distribution across all 50 US states plus the European Union (via CE Mark for DxCollect). Note that these tests are LDTs and have not been cleared or approved by the FDA, and require a physician order.

DxTerity generates revenue through three streams: per-test laboratory diagnostic services ordered by physicians (including via at-home DxCollect kits), sale of DxCollect collection devices, and custom development services — Clinical Trial Assays (CTAs) and Companion Diagnostics (CDx) — for biopharmaceutical partners engaged in autoimmune drug development. Customer segments include rheumatology practices and academic medical centers ordering tests, biopharmaceutical companies (including multiple top-10 global firms) using DxCollect for clinical trial patient stratification, and nonprofit research organizations such as the Lupus Research Alliance and Lupus Therapeutics. Distribution combines a physician-ordered domestic model, at-home self-collection, and direct B2B enterprise partnerships with pharma.

DxTerity firmographics

Firmographics
Name
DxTerity
Legal name
DxTerity Diagnostics Inc.
Website
https://dxterity.com
Company type
Private
Founded year
2006
Operating status
Operating
Headcount range
11–50 employees
Short description
DxTerity is a California-based molecular diagnostics company that runs a CAP-accredited, CLIA-certified laboratory offering RNA-based genomic tests and at-home blood collection devices for autoimmune disease management, serving physicians, autoimmune patients, and biopharmaceutical partners developing companion diagnostics.
Ownership category
akta.pro rank

DxTerity industry classification

Industry
Product category
Molecular Diagnostics
NAICS
Medical Laboratories (621511), In-Vitro Diagnostic Substance Manufacturing (325413)
SIC
In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLAHAHAJ
Diabetes Digital Therapeutics & Dose Decision Support (Bolus Calculators)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Diabetes Care Devices (CGM, Insulin Delivery)
SECONDARYHLAAALAN
Laboratory Developed Tests (LDTs) & Specialized Clinical Lab Assays
SECONDARYHLAAALAF
Companion Diagnostics (CDx) & Therapy Selection Assays
SECONDARYHLAAAMAL
Biomarker Assay & Reagent Development (LDT/IVD assay design, antibodies/standards/controls)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAAALAK
Autoimmune & Allergy Diagnostics

Keywords

  • RNA-based diagnostics
  • Autoimmune disease testing
  • Companion diagnostics development
  • Clinical trial assays
  • Blood collection devices

Where DxTerity is headquartered

Location

Headquarters

HQ city
Torrance
HQ country
United States
HQ region
North America

Offices1 record

Markets served

DxTerity business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

  1. Laboratory Testing Services: RNA-based diagnostic testing services performed in DxTerity's CAP-accredited, CLIA-certified laboratory. Tests ordered by physicians for patients with autoimmune diseases. Revenue generated per test with 7 business day turnaround time available.
  2. DxCollect Products: Sale of blood collection products including DxCollect MicroCollection Device (MCD) and Blood Collection Tube (BCT). Products enable fingerstick self-collection with 14-day RNA stabilization at room temperature for shipping.
  3. Development Services: Custom diagnostic development services for pharmaceutical companies including Clinical Trial Assays (CTA) and Companion Diagnostics (CDx). Services span from concept through commercialization including assay design, regulatory guidance, and manufacturing support.

Pricing tiers

ModelBillingPrice
OtherPay-as-you-goLaboratory testing services - physician-ordered tests

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

DxTerity product offering

Product offering

Core offering

DxTerity operates a CAP-accredited, CLIA-certified clinical laboratory that develops and delivers RNA-powered precision diagnostics for autoimmune diseases. The portfolio includes physician-ordered tests (Type 1 Interferon and Modular Immune Profile), proprietary at-home blood collection devices (DxCollect MCD and BCT) with 14-day ambient RNA stabilization, a CLPA-based testing platform (DxDirect), and custom Clinical Trial Assay and Companion Diagnostic development services for pharmaceutical partners.

Product overview

DxTerity offers a unified portfolio of RNA-based diagnostic products organized around two core platforms: DxCollect (blood collection devices) and DxDirect (testing platform). The DxCollect product line includes the MicroCollection Device (MCD) for fingerstick self-collection and the Blood Collection Tube (BCT) for venipuncture, both providing 14-day ambient RNA stabilization. The DxDirect platform enables high-throughput RNA testing without sample purification. Testing products include the Type 1 Interferon (IFN-1) focused assay and the Modular Immune Profile (MIP) targeted panel assay. The company also provides Development Services for pharmaceutical partners including assay design, clinical studies, regulatory guidance, and manufacturing for companion diagnostics.

Differentiator

Problem solved

Functional benefit

Brands

  • DxDirect: CLPA-based testing platform for direct-from-blood and tissue RNA testing using non-enzymatic chemical ligation technology.
  • DxCollect

Products and services

  • Type 1 Interferon (IFN-1) Test Focused assay measuring interferon pathway activity to identify SLE patients more likely to experience moderate to severe disease, helping identify candidates for targeted therapies such as anifrolumab. Requires a physician order.
  • Modular Immune Profile (MIP) Test Targeted panel assay providing broad immune system analysis including gene signatures for IFN-1, B-cells, T-cells, plasmablasts, neutrophils, and other immune pathways to characterize autoimmune disease and therapeutic response.
  • DxCollect MCD (MicroCollection Device) Finger stick self-collection device enabling blood draw with 14-day RNA stabilization at room temperature, allowing ambient shipping for DNA and RNA genomic testing without dry ice.
  • DxCollect BCT (Blood Collection Tube) Evacuated blood draw tube (1 mL draw) with 14-day ambient RNA stabilization, compatible with standard venipuncture workflows.
  • DxDirect Kits RNA-based testing kits utilizing a unique analytical process that eliminates sample purification and enables high-throughput processing (up to 1500 samples per day per system, 6 hour sample-to-answer).
  • Development Services Custom diagnostic development services for pharmaceutical companies including assay design, analytical validation, clinical studies, regulatory guidance, manufacturing, and data management for Clinical Trial Assays (CTA) and Companion Diagnostics (CDx).

Quantifiable outcome

  • Over 1 million tests processed
  • +3 more outcomes

Companies that use DxTerity

Customer profile

Named customers3 records

Segments3 records

Ideal customer profiles3 records

DxTerity technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature4 records

DxTerity partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered flagship and core.

  • Lupus Research AllianceflagshipStrategic or Co-development Partner · 23 May 2023Strategic partnership for the 5-year Lupus Landmark Study - a prospective longitudinal study targeting enrollment of up to 3,500 adults diagnosed with systemic lupus erythematosus (SLE). DxTerity provides testing using its Modular Immune Profile (MIP) assay including gene signatures for IFN-1, B-cells, T-cells, and other immune pathways. The study aims to provide real-world data and clinical samples to evaluate therapy effectiveness and power precision medicine development for SLE.
  • Lupus TherapeuticsflagshipStrategic or Co-development Partner · 23 May 2023Clinical research affiliate of Lupus Research Alliance collaborating on the Lupus Landmark Study. Partnership enables patient-centric, collaborative research resource (Lupus Nexus) for accelerating personalized treatments in lupus through large-scale genomic monitoring.
  • Pharmaceutical Companies (Multiple)coreStrategic or Co-development Partner · 27 February 2020DxCollect device deployed for patient stratification and monitoring in large-scale, direct-to-patient clinical studies. Multiple pharmaceutical companies use DxCollect for RNA preservation in clinical trials. Trusted by top ten global bio-pharmaceutical companies according to company statements.
  • Biotech and Pharmaceutical Industry ParticipantscoreStrategic or Co-development PartnerDxTerity has partnered with biotech and pharmaceutical industry participants in autoimmune to identify emerging biomarkers in therapeutic targeting. Targeted panel tests seek to establish claims across diagnostic, prognostic, and theranostic testing aims. Active in clinical trials with ongoing regulatory filings to establish standardized testing in clinical practice.

Scale indicators9 records

Recent moves6 records

Expansion highlights5 records

DxTerity competitors and assessment

Company assessment

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

DxTerity social profiles

Digital presence

DxTerity compliance and trust

Trust signal

Compliance11 records

DxTerity financial estimates

Financial estimate

Revenue estimate

Valuation estimate

DxTerity leadership team

Management profile

Number of profiles

Profiles1 record

DxTerity funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

DxTerity M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about DxTerity

What does DxTerity do?

DxTerity operates a CAP-accredited, CLIA-certified clinical laboratory that develops and delivers RNA-powered precision diagnostics for autoimmune diseases. The portfolio includes physician-ordered tests (Type 1 Interferon and Modular Immune Profile), proprietary at-home blood collection devices (DxCollect MCD and BCT) with 14-day ambient RNA stabilization, a CLPA-based testing platform (DxDirect), and custom Clinical Trial Assay and Companion Diagnostic development services for pharmaceutical partners.

Is DxTerity a public or private company?

DxTerity is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was DxTerity founded?

DxTerity was founded in 2006. It employs 11 to 50 people.

Where is DxTerity based?

DxTerity is headquartered in Torrance, United States, in the North America region.

How does DxTerity make money?

Three revenue lines are on record. Laboratory Testing Services are the primary driver. The others are dxCollect Products and development Services.

Does DxTerity have an API?

No public API is recorded for DxTerity.

What industry is DxTerity in?

DxTerity's product category is Molecular Diagnostics. Its primary akta.pro industry code is HLAHAHAJ, Diabetes Digital Therapeutics & Dose Decision Support (Bolus Calculators), with a secondary code of HLAAALAN, Laboratory Developed Tests (LDTs) & Specialized Clinical Lab Assays. Its NAICS code is 621511 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireDxTerity Diagnostics Announces the Launch of IFN-1 Test for LupusDxTerity Diagnostics announced the commercial launch of its IFN-1 Test for patients with Systemic Lupus Erythematosus (lupus), the first commercially available IFN-1 gene expression assay that measures expression levels of 4 genes to identify patients as IFN-1 high or low. The test measures Type-1 Interferon, a key biomarker associated with SLE disease severity and risk of lupus nephritis, providing information to guide treatment decisions. The launch coincides with the availability of the FDA-approved Type-1 Interferon receptor blocking therapy anifrolumab, giving rheumatologists a new tool for precision medicine in lupus management.PR NewswireDxTerity Diagnostics Begins Enrollment in the ELEVATE Clinical Study for LupusDxTerity Diagnostics announced the opening of enrollment in the ELEVATE observational clinical study for patients with Systemic Lupus Erythematosus (SLE or lupus) on May 27, 2022. The study will investigate biomarkers including Type-1 Interferon expression and explore relationships between these biomarkers and response to therapies such as Anifrolumab, building on findings from the previous LIFT study which identified IFN-1 as a key indicator of SLE disease prognosis. The research aims to advance precision medicine for lupus by developing diagnostic tests and potentially new personalized treatments, addressing a significant unmet need given only two new drugs have been approved for lupus in the past 60 years.PR NewswireDxTerity Diagnostics Announces "A Safe and Joyful 2022 Program" for Its PCR-Based Covid-19 TestDxTerity Diagnostics announced a 20% discount on its saliva-based at-home PCR COVID-19 test through January 10, 2022, on Amazon.com, positioning the offer as a convenient solution for holiday travelers facing test shortages and long clinic wait times. The test is FDA emergency use authorized, PCR-based with over 99% of results returned within 48 hours, and has been verified to detect the Omicron variant. The company is an ISO 13485-certified genomics company with a CLIA-licensed, CAP-accredited laboratory near Los Angeles, led by Founder and CEO Bob Terbrueggen.PR NewswireDxTerity Diagnostics Announces its OSHA Emergency Temporary Standard (ETS) Compliance-Ready COVID-19 Employer Screening ServiceDxTerity Diagnostics announced its SafeWorkDx subscription service, which meets OSHA's November 2021 Emergency Temporary Standard COVID-19 guidelines and is now available for employers seeking compliant testing and employee data management solutions. The service uses PCR testing at DxTerity's CLIA laboratory with results delivered to over 98% of employees within 24 hours and 99% within 48 hours, accessible through a HIPAA-compliant encrypted portal for both employees and human resources. The company stated employers will be looking for improved health monitoring tools given WHO's warning of a potential European COVID-19 resurgence.LA Business JournalDxTerity Develops At-Home Covid-19 TestingDxTerity Diagnostics developed a home saliva test for employee Covid-19 screening, with results in 48 hours. The company plans to submit its RNA-based test to the FDA for authorization around July 6. It also aims to distinguish flu from Covid in fall and winter.PR NewswireDxTerity Receives CE Mark for DxCollect® Fingerstick Blood RNA Stabilization DeviceDxTerity Diagnostics has received CE Mark approval for its DxCollect MicroCollection Tube, a fingerstick blood collection device that stabilizes RNA and DNA samples at room temperature, eliminating the need for dry ice shipping. The device is already being used by pharmaceutical companies for patient stratification and monitoring in clinical studies. The company is now pursuing FDA approval for home testing of systemic lupus erythematosus patients in conjunction with its Modular Immune Profile Assay.PR NewswireDxTerity Names Brett Swansiger Chief Commercialization OfficerDxTerity Diagnostics announced the hiring of Brett Swansiger as Chief Commercialization Officer on February 4, 2020. Swansiger brings over 20 years of commercial leadership experience in molecular diagnostics and pharmaceuticals, having previously held senior roles at MDxHealth Inc. and Agendia Inc. He will be responsible for building DxTerity's US market position through strategic partnerships and establishing payer contracts for the company's newly available IFN-1 test for systemic lupus erythematosus.PR NewswireDxTerity to Present at 12th Annual Canaccord Genuity Medical Technology & Diagnostics ForumDxTerity announced that Founder and CEO Bob Terbrueggen and SVP James Healy are scheduled to present at the 12th Annual Canaccord Genuity Medical Technology & Diagnostics Forum on November 15, 2018 at the Westin Grand Central in New York. The company also highlighted recent activities including presenting findings from two direct-to-patient clinical studies at the 2018 ACR/ARHP Annual Meeting and introducing its Autoimmune Profile Test, which is being developed to provide gene expression analysis of 12 immune-related disease pathways through an at-home blood test. DxTerity has begun early recruitment into its AIP Registry, an academic-industry consortium aimed at accelerating autoimmune disease research.PR NewswireDxTerity Announces Presentations from Lupus and Multiple Sclerosis Studies at the 2018 ACR/ARHP Annual MeetingDxTerity announced that data from systemic lupus erythematosus (SLE) and multiple sclerosis (MS) studies will be presented at the 2018 ACR/ARHP Annual Meeting in Chicago, demonstrating the company's Autoimmune Profile Test for at-home monitoring of autoimmune diseases. The LIFT study showed that Type 1 interferon levels correlate significantly with disease severity, ethnicity, and age at diagnosis in SLE patients, with higher IFN levels found in African Americans (68.1%) and Asians (90.6%) compared to Caucasians (31%). A separate study demonstrated that online direct-to-patient recruitment via Facebook and lupus bloggers enrolled over 1,000 participants in under six weeks, offering a cost-effective model for clinical trial enrollment.PR NewswireDxTerity Announces Preliminary Results from the LIFT Study will be Presented at the 2018 Annual European Congress of RheumatologyDxTerity announced that data from its LIFT study on interferon gene expression in systemic lupus erythematosus patients will be presented at the EULAR meeting in Amsterdam. The study used the DxCollect Fingerstick Collection Kit for self-collected blood samples. The company aims to provide real-world insights for personalized lupus care.